| Fatty Liver Disease Now Global, Terns Pharma Aims for NASH in China | Alex Lash | 04/04/18 | San Francisco |
| Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers | Alex Lash | 04/22/17 | San Francisco |
| With $20M, UCSD Spinout Jecure To Press New Attack On NASH | Frank Vinluan | 02/15/17 | San Diego |
| Acelity Sells LifeCell Tissue Repair Unit to Allergan for $2.9B | David Holley | 12/20/16 | Texas |
| Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More | Ben Fidler | 11/11/16 | National |
| Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More | Alex Lash | 09/23/16 | National |
| With Tobira Deal, Allergan Keeps Shopping For “Questionable” Assets | Alex Lash | 09/20/16 | San Francisco |
| Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease | Alex Lash | 05/28/16 | New York |
| West Coast Bio Roundup: Pfizer’s BBC Ghosts, Gilead’s NASH, HLI’s Cash | Alex Lash | 04/07/16 | San Francisco |
| As Rivals Make News, Intercept Heads To Daylong Hearing For Liver Drug | Alex Lash | 04/06/16 | New York |
| West Coast Bio Roundup: CRISPR Patent, HCV Data, Verily Digs & More | Alex Lash | 02/19/16 | San Francisco |
| West Coast Bio Roundup: Google/Insel, SeaGen, Avalon, Alector & More | Alex Lash | 09/18/15 | San Francisco |
| Well-Funded NGM Bio Nabs $200M To Boost Merck’s Metabolic Pipeline | Alex Lash | 02/23/15 | San Francisco |
